Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial
Authors: Jan H. Cornel
E. Magnus Ohman
Benjamin Neely
Peter Clemmensen
Piyamitr Sritara
Dmitry Zamoryakhin
Paul W. Armstrong
Dorairaj Prabhakaran
Harvey D. White
Keith A.A. Fox
Paul A. Gurbel
Matthew T. Roe
Alkmaar Medical Centre
Duke Clinical Research Institute
Duke University Medical Center
Kobenhavns Universitet
Mahidol University
Daiichi Sankyo Development Ltd
University of Alberta
Centre for Chronic Disease Control
Auckland City Hospital
University of Edinburgh
Sinai Center for Thrombosis Research
Keywords: Medicine
Issue Date: 1-Jan-2014
Citation: American Heart Journal. Vol.168, No.1 (2014)
Abstract: Background To further explore the impact of smoking on antiplatelet activity and treatment response, we evaluated time-dependent relationships between smoking status with on-treatment platelet reactivity and clinical outcomes for prasugrel vs. clopidogrel in patients with acute coronary syndromes managed medically without revascularization. Methods and Results A total of 7062 patients aged <75 years from the primary TRILOGY ACS cohort randomized to prasugrel vs. clopidogrel were evaluated through 30 months by baseline and time-dependent smoking status with adjusted proportional-hazards models. A total of 1613 participants (23%) were included in a platelet function sub-study evaluating serial P2Y12 reaction unit (PRU) measurements. Current smokers (n = 1566 [22%]) at baseline had fewer comorbidities compared with non-smokers; nearly half quit smoking during follow-up. Although median on-treatment PRU values were lower with prasugrel vs. clopidogrel, persistent smokers had lower serial PRU values in both treatment groups compared with non-smokers, with no differential interaction of treatment response by smoking status. The frequency of cardiovascular death, myocardial infarction, or stroke in current smokers was significantly lower with prasugrel (11.7%) vs. clopidogrel (18.6%), but there was no difference in non-smokers (13.8% vs. 13.7%), with significant interaction between treatment and baseline smoking status (P =.0002). Bleeding events occurred more frequently in prasugrel-treated patients with no significant interaction between treatment and baseline smoking status. Conclusions Among medically managed ACS patients <75 years of age, the risk of ischemic outcomes was significantly reduced with prasugrel vs. clopidogrel among smokers vs. non-smokers. No interaction between on-treatment platelet reactivity and smoking status was found. © 2014 Mosby, Inc.
ISSN: 10976744
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.